PSMA/NKG2DL multi-specific CAR-T cell therapy - Celyad Oncology
Latest Information Update: 10 Dec 2023
At a glance
- Originator Celyad Oncology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours